Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in China. Nowadays, China is emerging as important innovator ...